Literature DB >> 1469465

Therapy-related myelodysplastic syndrome in children with medulloblastoma following MOPP chemotherapy.

A Hayani1, D H Mahoney, L D Taylor.   

Abstract

Between 1978 and 1988, 20 children with medulloblastoma (MB) of the brain were treated postoperatively with MOPP (nitrogen mustard, vincristine, prednisone, and procarbazine). All but one received post-operative radiation prior to MOPP. Eight of 20 patients remained in continuous complete remission from MB, two of whom eventually developed myelodysplastic syndrome (MDS). Following resection of MB at age 12 months, one patient was treated with 24 courses of MOPP over 2 years without radiation therapy. She developed pancytopenia, and MDS was diagnosed 19 months after the completion of MOPP. Analysis of unstimulated bone marrow (BM) chromosomes showed structural abnormalities involving chromosomes 7, 10, 17, and 21. Eight months later, MDS evolved into acute myeloid leukemia. The second patient was diagnosed with MB at age 7 years and received postoperative craniospinal radiation followed by 12 courses of MOPP over one year. Five months after completion of MOPP, she developed MDS with monosomy 7 on chromosome analysis of bone marrow cells. Therapy-related MDS may be a complication of MOPP chemotherapy for MB in young children.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1469465     DOI: 10.1007/bf00170945

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  15 in total

1.  Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities.

Authors:  J Whang-Peng; R C Young; E C Lee; D L Longo; G P Schechter; V T DeVita
Journal:  Blood       Date:  1988-02       Impact factor: 22.113

Review 2.  Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease.

Authors:  J M Andrieu; N Ifrah; C Payen; J Fermanian; Y Coscas; G Flandrin
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

3.  Second malignant neoplasms in children: an update from the Late Effects Study Group.

Authors:  A T Meadows; E Baum; F Fossati-Bellani; D Green; R D Jenkin; B Marsden; M Nesbit; W Newton; O Oberlin; S G Sallan
Journal:  J Clin Oncol       Date:  1985-04       Impact factor: 44.544

4.  Brain tumors in the very young child. Postoperative chemotherapy in combined-modality treatment.

Authors:  M E Horowitz; R K Mulhern; L E Kun; E Kovnar; R A Sanford; J Simmons; F A Hayes; J J Jenkins
Journal:  Cancer       Date:  1988-02-01       Impact factor: 6.860

Review 5.  Therapy-related leukemia and myelodysplastic syndrome.

Authors:  H M Kantarjian; M J Keating
Journal:  Semin Oncol       Date:  1987-12       Impact factor: 4.929

6.  Survival and neurologic outcome of infants with medulloblastoma treated with surgery and MOPP chemotherapy. A preliminary report.

Authors:  T Z Baram; J van Eys; R E Dowell; A Cangir; B Pack; J M Bruner
Journal:  Cancer       Date:  1987-07-15       Impact factor: 6.860

7.  Molecular characterization of chromosome 7 long arm deletions in myeloid disorders.

Authors:  J Kere; T Ruutu; R Lahtinen; A de la Chapelle
Journal:  Blood       Date:  1987-11       Impact factor: 22.113

8.  Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders.

Authors:  H P Koeffler; D Heitjan; R Mertelsmann; J E Kolitz; P Schulman; L Itri; P Gunter; E Besa
Journal:  Blood       Date:  1988-03       Impact factor: 22.113

9.  MOPP regimen as primary chemotherapy for brain tumors in infants.

Authors:  J van Eys; A Cangir; D Coody; B Smith
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

10.  Myeloid neoplasia in children treated for solid tumours.

Authors:  C H Pui; M L Hancock; S C Raimondi; D R Head; E Thompson; J Wilimas; L E Kun; L C Bowman; W M Crist; C B Pratt
Journal:  Lancet       Date:  1990-08-18       Impact factor: 79.321

View more
  4 in total

Review 1.  Treatment-related myelodysplasia in patients with primary brain tumors.

Authors:  Joachim M Baehring; Peter W Marks
Journal:  Neuro Oncol       Date:  2012-03-29       Impact factor: 12.300

Review 2.  Therapy-related myelodysplastic syndrome (t-MDS) in a patient with anaplastic astrocytoma: successful treatment with allogeneic bone marrow transplant.

Authors:  L R Rogers; N Janakiraman; C Kasten-Sportes; M L Rosenblum
Journal:  J Neurooncol       Date:  2001-05       Impact factor: 4.130

Review 3.  Acute leukemia following treatment of malignant glioma.

Authors:  J R Perry; M T Brown; J P Gockerman
Journal:  J Neurooncol       Date:  1998-10       Impact factor: 4.130

4.  A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia.

Authors:  Alfonso Quintás-Cardama; Naval Daver; Hawk Kim; Courtney Dinardo; Elias Jabbour; Tapan Kadia; Gautam Borthakur; Sherry Pierce; Jianqin Shan; Marylou Cardenas-Turanzas; Jorge Cortes; Farhad Ravandi; William Wierda; Zeev Estrov; Stefan Faderl; Yue Wei; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-05-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.